Taku Miyoshi Selected Research

camostat

8/2021	A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats.
10/2016	A serine protease inhibitor attenuates aldosterone-induced kidney injuries via the suppression of plasmin activity.
2/2016	Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model.
1/2015	The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
7/2013	The antifibrotic effect of a serine protease inhibitor in the kidney.
1/2009	Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Taku Miyoshi Research Topics

Disease

5	Hypertension (High Blood Pressure) 08/2021 - 01/2005
5	Fibrosis (Cirrhosis) 10/2016 - 10/2012
3	Wounds and Injuries (Trauma) 08/2021 - 07/2006
2	Proteinuria 08/2021 - 10/2012
2	Ureteral Obstruction 10/2016 - 07/2013
2	Chronic Renal Insufficiency 02/2016 - 01/2015
1	Rodent Diseases 08/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2021
1	Premature Aging 01/2020
1	Sensorineural Hearing Loss 01/2020
1	Kidney Diseases (Kidney Disease) 10/2016
1	Infections 02/2016
1	IGA Glomerulonephritis (IGA Nephropathy) 02/2016
1	Insulin Resistance 03/2014
1	Chronic Kidney Failure (Chronic Renal Failure) 10/2012
1	Hypertrophy 10/2012
1	Calciphylaxis 07/2006
1	Skin Ulcer 07/2006
1	Focal Infection 07/2006
1	Renal hypouricemia 04/2005
1	Anemia 08/2004
1	Hypercalcemia (Milk Alkali Syndrome) 03/2003
1	Polyuria 03/2003
1	Hyponatremia 01/2003
1	Pancreatitis 01/2003
1	Hyperkalemia 01/2003
1	Disseminated Intravascular Coagulation 01/2003
1	Hyperaldosteronism (Conn Syndrome) 02/2002

Drug/Important Bio-Agent (IBA)

8	Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA 08/2021 - 01/2003
6	camostatIBA 08/2021 - 01/2009
5	SaltsIBA 10/2016 - 01/2005
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 02/2002
4	prostasinIBA 03/2014 - 02/2002
3	Serine Proteases (Serine Protease)IBA 08/2021 - 03/2014
3	AldosteroneIBA 10/2016 - 02/2002
3	Messenger RNA (mRNA)IBA 01/2015 - 02/2002
2	Adenine FDA LinkGeneric 02/2016 - 01/2015
2	CollagenIBA 07/2013 - 10/2012
2	Amiloride (Midamor)FDA LinkGeneric 08/2009 - 01/2005
1	Fibrinolysin FDA Link 10/2016
1	Telmisartan (Micardis)FDA Link 02/2016
1	SteroidsIBA 02/2016
1	AntioxidantsIBA 01/2015
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2015
1	Toll-Like Receptor 4IBA 03/2014
1	Hydroxyproline (4 Hydroxyproline)IBA 07/2013
1	Plasminogen Activators (Plasminogen Activator)IBA 07/2013
1	Transforming Growth Factors (Transforming Growth Factor)IBA 07/2013
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 07/2013
1	Connective Tissue Growth FactorIBA 07/2013
1	CreatinineIBA 10/2012
1	nephrinIBA 10/2012
1	Eplerenone (Inspra)FDA LinkGeneric 08/2009
1	Antihypertensive Agents (Antihypertensives)IBA 01/2009
1	Etidronic Acid (HEDP)FDA LinkGeneric 07/2006
1	Anti-Bacterial Agents (Antibiotics)IBA 07/2006
1	urate transporterIBA 04/2005
1	Uric Acid (Urate)IBA 04/2005
1	Epithelial Sodium ChannelsIBA 01/2005
1	IronIBA 08/2004
1	Calcium-Sensing ReceptorsIBA 03/2003
1	PotassiumIBA 01/2003
1	nafamostatIBA 01/2003
1	SodiumIBA 01/2003

Therapy/Procedure

3	Renal Dialysis (Hemodialysis) 01/2020 - 08/2004
3	Therapeutics 02/2016 - 07/2006
1	Tonsillectomy 02/2016
1	Nephrectomy 10/2012
1	Oral Administration 07/2006